Edwards Lifesciences (NYSE:EW) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents. This just beats out Wall Street's estimate of 69 cents per share. It's also better than the 66 cents per share reported in the same period of the year prior. However, the company's revenue of $1.63 billion failed to impress investors. That comes in below analysts' estimate of $1.65 billion for the perio ...

Financial Data and Key Metrics Changes - Total company sales for Q2 2024 reached $1.6 billion, reflecting an 8% increase on a constant currency basis compared to the previous year [10] - Adjusted EPS was $0.70, while GAAP EPS was $0.61, which included one-time separation expenses related to the sale of Critical Care [36][50] - Adjusted gross profit margin was 77.1%, down from 77.7% in the same period last year, primarily due to foreign exchange impacts [39] Business Line Data and Key Metrics Changes - TAVR sales in Q2 were $1.04 billion, a 6% year-over-year increase, which was lower than expected [13] - TMTT sales reached $83 million, representing a 75% increase year-over-year, driven by the PASCAL repair system and early commercial introduction of EVOQUE [23] - Surgical structural heart sales were $264 million, up 5% from the prior year, supported by strong adoption of premium surgical technologies [29] - Critical Care sales were $246 million, increasing 7% year-over-year, led by pressure monitoring devices [30] Market Data and Key Metrics Changes - In the US, TAVR sales growth was slightly below the global constant currency growth rate, impacted by increased competition and hospital workflow pressures [16] - Outside the US, TAVR sales growth was slightly above the global average, with double-digit growth in Japan driven by SAPIEN 3 Ultra RESILIA [20] - The company anticipates TAVR sales growth for the second half of the year to be between 5% to 7%, down from previous guidance of 8% to 10% [21] Company Strategy and Development Direction - The company announced acquisitions of JenaValve and Endotronix to expand into new therapeutic areas, specifically aortic regurgitation and heart failure [12][31] - The strategic focus remains on advancing TAVR and TMTT technologies, with a commitment to improving patient care and expanding market share [45] - The company is confident in its long-term growth strategy, aiming for sustainable double-digit revenue and earnings growth [51] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that TAVR growth was below expectations due to increased competition and hospital workflow challenges, but remains optimistic about long-term opportunities [11][70] - The company is focused on improving referral and treatment rates for patients with severe symptomatic aortic stenosis through initiatives like the ENACT patient activation program [18] - Management expects minimal revenue contribution from recent acquisitions in 2025 but anticipates long-term growth opportunities from these investments [34][43] Other Important Information - The company plans to close the sale of Critical Care by late Q3 2024, with one-time costs associated with the sale impacting financials [42] - The company maintains a strong balance sheet with approximately $2 billion in cash and short-term investments as of June 30 [42] Q&A Session Summary Question: What would be compelling for early TAVR? - Management indicated that a compelling case for early intervention would need to demonstrate significant benefits, such as mortality reduction, to drive TAVR growth [56][58] Question: What is the outlook for TAVR growth? - Management acknowledged that TAVR growth has been slower than expected, but they believe hospitals will adapt and scale to support increasing volumes over time [70][74] Question: How does the company view the TAVR market's long-term potential? - Management remains confident in the long-term potential of the TAVR market, with a previously stated total addressable market of $10 billion by 2028, although they are not updating guidance at this time [95][96]

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Net Sales- Outside of the United States: $569.10 million compared to the $684.70 million average estimate based on three analysts. The reported number represents a change of -10.4% year over year. Net Sales- United States: $816.80 million versus the three-analyst average e ...

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.69 on $1.62 billion in revenues for the coming quarter and $2.77 on $6.56 billion in revenues for the current fiscal year. What's Next for Edwards Lifesciences? Edwards Lifesciences (EW) came out with quarterly earnings of $0.70 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.66 per share a year ago. These figures ...

Edwards Lifesciences Corporation (EW) announced its decision to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company. This follows Edwards Lifescience's initial investment in Innovalve in 2017, following which Innovalve has shown progress and early clinical success. The acquisition is set to bolster Edwards Lifesciences' existing mitral innovations, providing advanced TMVR solutions to address significant unmet needs in structural heart disease. Significan ...

Earnings Expectations - The market expects Edwards Lifesciences to report a year-over-year increase in earnings and revenues for the quarter ended June 2024 [1] - The company is expected to post quarterly earnings of $0.70 per share, representing a year-over-year change of +6.1% [2] - Revenues are expected to be $1.65 billion, up 8.1% from the year-ago quarter [12] Earnings ESP and Zacks Rank - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being a more recent version of the consensus estimate [4] - A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [6] - Edwards Lifesciences currently has a Zacks Rank of 4 (Sell) [7] - The company's Earnings ESP is +0.58%, indicating that the Most Accurate Estimate is higher than the Zacks Consensus Estimate [23] Historical Performance and Estimate Revisions - For the last reported quarter, Edwards Lifesciences delivered a surprise of +3.13%, with actual earnings of $0.66 per share compared to the expected $0.64 [8] - Over the last four quarters, the company has beaten consensus EPS estimates two times [22] - The consensus EPS estimate for the quarter has been revised 0.14% lower over the last 30 days [21] Predictive Insights - Stocks with a positive Earnings ESP and a solid Zacks Rank produce a positive surprise nearly 70% of the time [6] - A positive or negative Earnings ESP reading theoretically indicates the likely deviation of actual earnings from the consensus estimate, but the model's predictive power is significant for positive ESP readings only [14] - It is difficult to predict an earnings beat with confidence for stocks with negative Earnings ESP readings and/or a Zacks Rank of 4 (Sell) or 5 (Strong Sell) [20] Market Reaction and Future Expectations - The stock might move higher if key numbers top expectations in the upcoming earnings report, expected to be released on July 24 [11] - Management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations [19]

Edwards Lifesciences Corporation (EW) is scheduled to report second-quarter 2024 results on Jul 24, after market close. Q2 Estimates The Zacks Consensus Estimate for second-quarter 2024 net earnings of 70 cents per share indicates a 6.1% improvement from the year-ago reported figure. Estimate Revision Trend Ahead of Earnings Let's briefly look at how things have progressed for the MedTech major leading up to this announcement. Similar to the last reported quarter, Edwards Lifesciences is likely to have gain ...

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has determined that its in the best interest of the Company to return capital to its shareholders by way of a reduction in stated capital of the Company. On Behalf of the Board Further details in respect of the Capital Reduction, the Distribution and special general meeting matters will be announced when determined and will be provided in t ...

Edwards Lifesciences Corporation (EW) is well poised for growth in coming quarters, backed by the strength of a differentiated portfolio of advanced therapies. The company continues to witness strong performance of its SAPIEN 3 Ultra RESILIA platform, the leading platform in the United States and Japan. However, stiff rivalry and foreign exchange headwinds are a concern for EW's business. In the past six months, this Zacks Rank #3 (Hold) stock has gained 30.2% compared with an 18.1% rise of the industry and ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Edwards Lifesciences (EW) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Edwards Lifesciences is one of 1050 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measur ...